Emerging problem pathogens: A review of resistance patterns over time

International Journal of Infectious Diseases

Volumn 10, Issue SUPPL. 2, 2006, Pages S3-

  Akova, Murat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Antibiotic resistance

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; CYTARABINE; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; METICILLIN; PENICILLIN G; PIPERACILLIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TOBRAMYCIN; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CANCER PATIENT; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG SENSITIVITY; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; HUMAN; INFECTION COMPLICATION; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; PROPHYLAXIS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 33750501379     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(06)60002-7     Document Type: Article

References (29)

1. Viscoli C. Management of infection in cancer patients, studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer 38 Suppl 4 (2002) S82-S87
2. Wisplinghoff H., Seifert H., Wenzel R., et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36 9 (2003) 1103-1110
3. European Organization for Research and Treatment of Cancer (EORTC). International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 163 5 (1991) 951-958
4. Cometta A., Kern W., De Bock R., et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 37 3 (2003) 382-389
5. Collin B., Leather H., Wingard J., et al. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 33 7 (2001) 947-953
6. EORTC International Antimicrobial Therapy Project Group. Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. J Infect Dis 150 3 (1984) 372-379
7. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. JAMA 272 15 (1994) 1183-1189
8. Viscoli C., Castagnola E., Giacchino M., et al. Bloodstream infections in children with cancer: a multicentre surveillance study of the Italian Association of Paediatric Haematology and Oncology. Supportive Therapy Group-Infectious Diseases Section. Eur J Cancer 35 5 (1999) 770-774
9. Castagnola E., Caviglia I., Pistorio A., et al. Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution. Eur J Cancer 41 10 (2005) 1439-1445
10. Yadegarynia D., Tarrand J., Raad I., et al. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 37 8 (2003) 1144-1145
11. Akova M., Paesmans M., Calandra T., et al. A European organization for research and treatment of cancer-international antimicrobial therapy group study of secondary infections in febrile, neutropenic patients with cancer. Clin Infect Dis 40 2 (2005) 239-245
12. Calik N, Karaagaoglu E, Hascelik G, et al. Epidemiology of bacterial infections and risk factors for mortality in cancer patients. In: Program and Abstracts of Interscience Conference of Antimicrobial Agents and Chemotherapy, 2005, Washington DC, USA. K-1529.
13. Safdar A, Rodriguez G, Balakrishnan M, et al. Changing trends of bacteraemia in patients with cancer: analysis of 2080 quantative blood culture during 1998 and 2004. In: Program and Abstracts of European Congress of Clinical Microbiology and Infectious Diseases, 2006, Nice, France. P681.
14. Wisplinghoff H., Bischoff T., Tallent S., et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39 3 (2004) 309-317
15. Jones R., Stilwell M., Sader H., et al. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn Microbiol Infect Dis 54 2 (2006) 149-153
16. Schito G. The importance of the development of antibiotic resistance in Staphylococcus aureus. Clin Microbiol Infect 12 Suppl 1 (2006) 3-8
17. Doern G., Ferraro M., Brueggemann A., et al. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 40 4 (1996) 891-894
18. Han X., Kamana M., and Rolston K. Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases. J Clin Microbiol 44 1 (2006) 160-165
19. Ramphal R., Ambrose P., Pena C., et al. Extended-spectrum beta-lactamases and clinical outcomes: current data. Risk-factors for acquisition of extended-spectrum betalactamase-producing Escherichia coli among hospitalised patients. Clin Infect Dis 15 Suppl 4 (Apr 2006) S164-S172
20. Carratala J., Alcaide F., Fernandez-Sevilla A., et al. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis 20 5 (1995) 1169-1173
21. Marron A., Carratala J., Gonzalez-Barca E., et al. Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer. Clin Infect Dis 31 5 (2000) 1126-1130
22. Bruckner L., Korones D., Karnauchow T., et al. High incidence of penicillin resistance among alpha-hemolytic streptococci isolated from the blood of children with cancer. J Pediatr 140 1 (2002) 20-26
23. Mendes C., and Turner P. Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997-2000). Diagn Microbiol Infect Dis 41 4 (2001) 191-196
24. Ariffin H., Navaratnam P., Mohamed M., et al. Ceftazidimeresistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. Int. J Infect Dis 4 1 (2000) 21-25
25. Siu L., Lu P., Hsueh P., et al. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes. J Clin Microbiol 37 12 (1999) 4020-4027
26. De Bock R., Cometta A., Kern W., et al. Incidence of single agent Gram-negative bacteremias (SAGNB) in netropenic cancer patients (NCP) in EORTC-IATG trials of empiical therapy for febrile neutropenia. Program and Abstracts of 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (2001), American Society for Microbiology, Washington, DC, Chicago, USA 455 Abstract L-733.
27. Bucaneve G., Micozzi A., Menichetti F., et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353 10 (2005) 977-987
28. Kern W., Klose K., Jellen-Ritter A., et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 24 2 (2005) 111-118
29. Gafter-Gvili A, Paul M, Fraser A, et al. Effect of quinolone prophylaxis on resistance in afebrile neutropenic patients - systematic review. In: Program and Abstracts of European Congress of Clinical Microbiology and Infectious Diseases, 2006, Nice, France. P685.